Sophie J Bradley

List of Publications by Year
in descending order

24 papers	755 citations	516710 16 h-index	713466 21 g-index
26 all docs	26 docs citations	26 times ranked	1114 citing authors

#	Article	IF	Citations
1	DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacology and Translational Science, 2018, 1, 61-72.	4.9	143
2	M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. Journal of Clinical Investigation, 2016, 127, 487-499.	8.2	56
3	Quantitative Analysis Reveals Multiple Mechanisms of Allosteric Modulation of the mGlu5 Receptor in Rat Astroglia. Molecular Pharmacology, 2011, 79, 874-885.	2.3	54
4	Chemogenetics defines receptor-mediated functions of short chain free fatty acids. Nature Chemical Biology, 2019, 15, 489-498.	8.0	52
5	G protein-coupled receptor signalling in astrocytes in health and disease: A focus on metabotropic glutamate receptors. Biochemical Pharmacology, 2012, 84, 249-259.	4.4	51
6	Mapping physiological G protein-coupled receptor signaling pathways reveals a role for receptor phosphorylation in airway contraction. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4524-4529.	7.1	46
7	From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. Cell, 2021, 184, 5886-5901.e22.	28.9	44
8	Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nature Chemical Biology, 2020, 16, 240-249.	8.0	36
9	An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory. Journal of Biological Chemistry, 2016, 291, 8862-8875.	3.4	34
10	M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?. Advances in Pharmacology, 2020, 88, 277-310.	2.0	32
11	Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. Frontiers in Pharmacology, 2020, 11, 606656.	3.5	30
12	Inhibition of neuroinflammatory nitric oxide signaling suppresses glycation and prevents neuronal dysfunction in mouse prion disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
13	Design of Next-Generation G Proteinâ€“Coupled Receptor Drugs: Linking Novel Pharmacology and In Vivo Animal Models. Annual Review of Pharmacology and Toxicology, 2016, 56, 535-559.	9.4	26
14	Bitopic Binding Mode of an M₁ Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Molecular Pharmacology, 2018, 93, 645-656.	2.3	25
15	Effects of Positive Allosteric Modulators on Single-Cell Oscillatory Ca²⁺Signaling Initiated by the Type 5 Metabotropic Glutamate Receptor. Molecular Pharmacology, 2009, 76, 1302-1313.	2.3	24
16	Alterations in neuronal metabolism contribute to the pathogenesis of prion disease. Cell Death and Differentiation, 2018, 25, 1408-1425.	11.2	24
17	The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system. Neuropharmacology, 2018, 136, 421-426.	4.1	13
18	Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13

#	Article	IF	Citations
19	Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?. Frontiers in Pharmacology, 2022, 13, .	3.5	9
20	Employing novel animal models in the design of clinically efficacious GPCR ligands. Current Opinion in Cell Biology, 2014, 27, 117-125.	5.4	7
21	The M ₁ muscarinic receptor is present in situ as a ligand-regulated mixture of monomers and oligomeric complexes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	4
22	Muscarinic acetylcholine receptors in the central nervous system. Neuropharmacology, 2018, 136, 361.	4.1	0
23	Call for Papers: Advances in G Protein Coupled Receptor Signal Transduction. ACS Pharmacology and Translational Science, 2019, 2, 147-147.	4.9	0
24	Editorial for Advances in G Protein-Coupled Receptor Signal Transduction Special Issue. ACS Pharmacology and Translational Science, 2020, 3, 169-170.	4.9	0